Abnormal psychology

"The Yoga Therapy Renaissance" Sheds Light on an Increasingly Important Field

Retrieved on: 
Tuesday, March 26, 2024
Yoga as therapy, Health, Organization, Head, Yoga, Growth, Initiative, Exercise, Walking, Cardiology, Science, GWI, Education, Conditional sentence, International Association, Patient, Knowledge, Accreditation, Sleep, Research, T. K. V. Desikachar, Ebook, Chronic pain, Nature, Publication, Immunity, Meditation, Medicine, Evidence-based practice, Workplace, Fatigue, Abnormal psychology, Century, Loneliness, Rehabilitation, Health care

CHICAGO, March 26, 2024 /PRNewswire/ -- Yoga Therapy, an evidence-based practice used to treat chronic diseases, structural conditions and mental health issues, as well as foster wellbeing and personal growth, is taking root as a powerful tool to improve health and wellness, healing and more. However, it remains little understood by not only the public at large but also by healthcare professionals and many practitioners and teachers of more widespread forms of yoga. A new free eBook by Bija Bennett and industry experts, "The Yoga Therapy Renaissance: A New Wellness Modality for the 21st Century," covers the origins, evolution, growth, training programs, applications across industries and vast potential this distinct wellness modality has for modern healthcare.

Key Points: 
  • "Like yoga, a 5,000-year-old set of practices that has enjoyed exponential growth in the last decade, Yoga Therapy is an ancient modality that is flourishing once again," Bennett noted.
  • Yoga Therapy is a subset of yoga based on the therapeutic and clinical application of specific practices, but these therapeutic methods are now being incorporated into top healthcare systems' integrative medicine programs.
  • As a result, yoga therapists are increasingly earning the necessary certifications for this form of therapy and becoming engaged in clinical roles," Bennett, a certified yoga therapist, explained."
  • Her eBook, "The Yoga Therapy Renaissance," serves to:
    Validate Yoga Therapy's efficacy as a modern wellness modality and discipline built on a profound body of knowledge, experience and substantiated benefits;
    Differentiate Yoga Therapy as a distinct subspecialty within the wider discipline of yoga practice;
    Increase mainstream awareness of the holistic value and impact of Yoga Therapy; and
    Drive the adoption of Yoga Therapy in diverse industries and settings in both public and private sectors.

Clarity Child Guidance Center Breaks Ground on Vital Renovations to Increase Capacity for Children facing Mental Health Challenges

Retrieved on: 
Friday, December 29, 2023
Walking, Bipolar disorder, Work, Family, Ecosystem, Trauma, Adolescence, Clarity, Depression, Disability, Patient, Drainage, Phase 3, Mental, Numb, Language, Abnormal psychology, SAN, Mental health, Anxiety, Campaign, COVID, Nursing, Housekeeping, Schizophrenia, Suicidal ideation, ADHD, LCSW, Child

SAN ANTONIO, Dec. 29, 2023 /PRNewswire-PRWeb/ -- Clarity Child Guidance Center broke ground during a special ceremony on Wednesday, September 20, 2023, on renovations being made possible through its "HEROES: The Campaign for Clarity." When complete, this $16 million capital campaign will allow Clarity to serve an additional 1,000 kids a year—bringing the annual total to an annual average of 9,000 children and teens--ensuring that every child and family who needs behavioral health services can receive them. Currently, about 60% of children treated at Clarity are uninsured, underinsured or low-income. San Antonio-based Clarity Child Guidance Center--the only nonprofit in South Texas providing a continuum of mental health care for children ages 3-17 and their families to manage conditions ranging from ADHD and anxiety to suicidal ideation, bipolar disorder and/or schizophrenia—is indeed experiencing a 27% increase in inpatient hospitalizations, 19% increase in children who were suicidal, a 65% increase in inpatient treatment of kids that have never been seen in the mental health system before, and a 159% increase in the crisis services department. (More on Clarity below.)

Key Points: 
  • SAN ANTONIO, Dec. 29, 2023 /PRNewswire-PRWeb/ -- Clarity Child Guidance Center broke ground during a special ceremony on Wednesday, September 20, 2023, on renovations being made possible through its "HEROES: The Campaign for Clarity."
  • Currently, about 60% of children treated at Clarity are uninsured, underinsured or low-income.
  • "School violence, isolation of the pandemic, and return to the classroom for the increase in demand.
  • Bexar County Judge Peter Sakai and District 8 Councilman Manny Pelaez publicly reaffirmed their commitment to youth mental health for San Antonio area.

Eyenovia Reports Third Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Monday, November 13, 2023
CNS, Acquisition, Mydriasis, Audit committee, Telecanthus, Visual acuity, CFO, Headache, Net, Patient, Presbyopia, Research, Element, Tropicamide, Lomb, Growth, Inflammation, Vomiting, Intraocular pressure, ACE, ADT Inc., American Academy, Abnormal psychology, New Drug Application, Nausea, Tachycardia, Mouth, Hypersensitivity, NDA, Allied health professions, International Joint Commission, Photophobia, Psychotic Reaction, Cholinergic, Pilocarpine, Pallor, Reader's Digest, Blood pressure, Bausch, Carbachol, Near-sightedness, Allergy, FDA, Contact, Central nervous system, PDUFA, Hypertonia, Pharmaceutical industry, Management, Nursing, Telescopic sight, Video game, Euronext, Ophthalmology

NEW YORK, Nov. 13, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), a commercial-stage, topical ophthalmic company leveraging its Optejet® dispensing technology for both internally developed and acquired programs as well as out-licensing for additional indications, today announced its financial and operating results for the third quarter ended September 30, 2023.

Key Points: 
  • Advanced its Gen-2 Optejet device and anticipates shipping to MicroPine partners Bausch and Lomb and Arctic Vision by year-end 2023.
  • Research and development expenses totaled approximately $3.6 million for the third quarter of 2023 as compared to $3.9 million for the third quarter of 2022.
  • For the third quarter of 2023, general and administrative expenses were approximately $2.9 million, compared to $3.4 million for the third quarter of 2022.
  • Total operating expenses for the third quarter of 2023 were approximately $6.5 million compared to $7.2 million for the third quarter of 2022.

Talkiatry and Charlie Health Partner for Integrated Mental Healthcare Experience

Retrieved on: 
Thursday, December 14, 2023
Abnormal psychology, Family therapy, Case management, Adolescence, Mental health, IOP, Depression, DSM-IV codes, Patient, Anxiety, Partnership, PTSD, Nursing

Mental health crisis impacts one in five Americans, with just half of children and adolescents with diagnosable mental health problems receiving treatment.

Key Points: 
  • Mental health crisis impacts one in five Americans, with just half of children and adolescents with diagnosable mental health problems receiving treatment.
  • Leveraging innovative technology, the partners seek to provide an integrated care experience to young patients stepping up to virtual intensive outpatient care at Charlie Health and stepping down to ongoing psychiatric care at Talkiatry.
  • Both Talkiatry and Charlie Health aim to increase access to quality mental health care.
  • Dr. Caroline Fenkel, Chief Clinical Officer and Co-Founder of Charlie Health, added, "At Charlie Health, we're redefining the mental health treatment experience.

AviadoBio Announces FDA IND Clearance and Fast Track Designation for AVB-101 for the Treatment of Frontotemporal Dementia with Progranulin (GRN) Mutations

Retrieved on: 
Monday, November 6, 2023
Biotechnology, Pharmaceutical, Oncology, General Health, Health, FDA, Genetics, Clinical Trials, GRN, IND, Autosome, AAV, Food, Genetic, European Commission, Fast Track, Prevalence, Investigational New Drug, EC, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Apathy, Personality, Dementia, Civil service commission, Abnormal psychology, Frontotemporal dementia, Gene, Brain, Safety, Patient, Death, FTD, Granulin, Pharmaceutical industry

In addition, the FDA has granted Fast Track designation to AVB-101 for the treatment of FTD-GRN to slow disease progression.

Key Points: 
  • In addition, the FDA has granted Fast Track designation to AVB-101 for the treatment of FTD-GRN to slow disease progression.
  • Both the U.S. FDA and the European Commission (EC) granted orphan designation to AVB-101 for the treatment of FTD in 2022.
  • “The IND clearance and Fast Track designation of AVB-101 are important milestones for the FTD community and for our company.
  • Sadly, there are currently no disease-modifying therapies approved for the treatment of people living with frontotemporal dementia with progranulin mutations.

Eyenovia Reports Second Quarter 2023 Financial Results and Provides Business Update

Retrieved on: 
Thursday, August 10, 2023
Hypersensitivity, Blood pressure, Contact, Pallor, Central nervous system, Allergy, Mydriasis, Presbyopia, Cholinergic, Abnormal psychology, Tropicamide, Optometry, Pilocarpine, CNS, Sale, Tachycardia, Hypertonia, Intraocular pressure, Vomiting, ET, Photophobia, Russell, Patient, Physician, Psychotic Reaction, PDUFA, Nausea, Research, FDA, Headache, Visual acuity, Carbachol, Mouth, Cryptocurrency, Pharmaceutical industry, Property management, Medical device, Video game, Telescopic sight

NEW YORK, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ (tropicamide+phenylephrine ophthalmic spray) for mydriasis and developing the Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced its financial and operating results for the second quarter ended June 30, 2023.

Key Points: 
  • Advanced its pre-NDA presbyopia program, Apersure (Microline), and anticipates commencing the manufacture of registration batches in the fourth quarter of 2023.
  • Research and development expenses totaled approximately $2.8 million for the second quarter of 2023 as compared to $3.6 million for the second quarter of 2022.
  • For the second quarter of 2023, general and administrative expenses were approximately $3.1 million, compared to $3.5 million for the second quarter of 2022.
  • Total operating expenses for the second quarter of 2023 were approximately $6.0 million compared to $7.1 million for the second quarter of 2022.

Eyenovia Announces First Commercial Sale of Mydcombi™

Retrieved on: 
Thursday, August 3, 2023
Hypersensitivity, Blood pressure, Contact, US Foods, Pallor, Central nervous system, Mouth, Allergy, Mydriasis, Presbyopia, Cholinergic, Ophthalmology, Abnormal psychology, Tropicamide, Optometry, CNS, Pilocarpine, Sale, Tachycardia, Hypertonia, Intraocular pressure, Vomiting, Photophobia, Patient, Psychotic Reaction, Nausea, FDA, Headache, Visual acuity, Carbachol, Food, Phenylephrine, Pharmaceutical industry, Telescopic sight

NEW YORK, Aug. 03, 2023 (GLOBE NEWSWIRE) -- Eyenovia, Inc. (NASDAQ: EYEN), an ophthalmic technology company commercializing Mydcombi™ (tropicamide and phenylephrine hydrochloride ophthalmic spray) 1%/2.5% for mydriasis and developing the Optejet® device for use both in connection with its own drug-device therapeutic product candidates for presbyopia and pediatric progressive myopia as well as out-licensing for additional indications, today announced the first commercial sale of Mydcombi. Mydcombi was approved by the US Food and Drug Administration on May 8, 2023. The initial sale was to world-renowned board-certified ophthalmologist Dr. Nathan M. Radcliffe, who has become the first physician in the U.S. to incorporate Mydcombi into his daily practice.

Key Points: 
  • Mydcombi was approved by the US Food and Drug Administration on May 8, 2023.
  • The initial sale was to world-renowned board-certified ophthalmologist Dr. Nathan M. Radcliffe, who has become the first physician in the U.S. to incorporate Mydcombi into his daily practice.
  • The product should not be used in patients with known hypersensitivity to any component of the formulation.
  • To report SUSPECTED ADVERSE REACTIONS, contact Eyenovia, Inc. At 1-833-393-6684 or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch)

Survey: Majority of Schools Understaffed With Health Professionals As Challenges Grow

Retrieved on: 
Monday, July 24, 2023
Individualized Education Program, AMN, RNS, Life, IEP, Marie Cassidy, COVID-19, Social skills, Pathology, Abnormal psychology, Language, Bangladesh Technical Education Board, Government, Child, School, Student, Hospital, Nursing, Person-centered therapy, Adolescence, MOE, Caregiver

“Many public schools are struggling to find the healthcare professionals they need at a time when the fallout from COVID-19 and rising mental health challenges are driving demand for school-based caregivers,” said David Schmiesing, President of AMN Healthcare’s Schools division.

Key Points: 
  • “Many public schools are struggling to find the healthcare professionals they need at a time when the fallout from COVID-19 and rising mental health challenges are driving demand for school-based caregivers,” said David Schmiesing, President of AMN Healthcare’s Schools division.
  • According to the survey, 52% of public school administrators report their schools are understaffed with healthcare professionals.
  • The survey suggests that understaffing of healthcare professionals is common at a time when schools are facing a range of student health concerns, including poor physical health among many school age children.
  • “Like many types of healthcare facilities, schools are finding it difficult to staff the healthcare professionals they need.”
    The survey indicates that the majority of public schools (73%) use contract professionals to staff vacancies.

Boys & Girls Clubs of America Partners with Unite Us to Enhance Access to Health and Wellness Resources

Retrieved on: 
Thursday, July 20, 2023
Mental Health, Technology, Teens, Software, Family, Managed Care, General Health, Consumer, Health, Data Management, Partnership, Housing, Faith Divides Us – Death Unites Us, COVID-19, Unite, Abnormal psychology, Entrepreneurship, Boys & Girls Clubs of America, Boys & Girls Club, Transport, Food, Mental health, Toy, Club

With more than 5,000 Clubs across the nation, Boys & Girls Clubs of America provides supportive spaces, caring mentors, and life-enhancing programs to over 3.6 million young people.

Key Points: 
  • With more than 5,000 Clubs across the nation, Boys & Girls Clubs of America provides supportive spaces, caring mentors, and life-enhancing programs to over 3.6 million young people.
  • For over 160 years, Clubs have been anchors in communities, giving kids and teens access to resources that help them thrive.
  • In partnership with Unite Us, Boys & Girls Clubs of America will provide local Boys & Girls Clubs with free access to and training for their online platform with the goal of connecting Club members and their families to needed community support to bolster youth mental health.
  • “Boys & Girls Clubs across the country are dedicated to ensuring young people have access to what they need to reach their full potential,” said Jim Clark, President and CEO at Boys & Girls Clubs of America.

Bend Health Launches Virtual Neuropsychological Evaluations for Kids and Teens

Retrieved on: 
Tuesday, July 11, 2023
Learning, Depression, Tic disorder, IEP, Anxiety, ADHD, Spectrum, DSM-IV codes, Attention, Abnormal psychology, Language, Mental, Brain, Child, Adolescence, Nation, AI, Trauma, Mental health, Memory, Nursing, Bend

MADISON, Wis., July 11, 2023 /PRNewswire/ -- Bend Health, Inc. ("Bend") a leading national, virtual pediatric behavioral care provider that raised $32 million in capital last year, today announced an expansion of its child and adolescent mental health care services to include virtual neuropsychological evaluations. Neuropsychological testing from Bend is available nationwide and in the District of Columbia.

Key Points: 
  • MADISON, Wis., July 11, 2023 /PRNewswire/ -- Bend Health, Inc. ("Bend") a leading national, virtual pediatric behavioral care provider that raised $32 million in capital last year, today announced an expansion of its child and adolescent mental health care services to include virtual neuropsychological evaluations.
  • Neuropsychological evaluations are mandatory in some states to access IEPs (individualized educational programs) or specialized services.
  • Mental health diagnoses for children have increased exponentially, with one in four U.S. kids and teens having a diagnosed mental, emotional, or behavioral disorder, leading to an overwhelming demand for pediatric mental health care.
  • Its collaborative care model combines virtual video visits, chat messaging, and integrated digital experiences to provide skills for kids, teens, and providers that support long-term mental health resilience and wellness.